For example, Luxturna (Spark Therapeutics), the first ocular gene therapy approved by the FDA in 2017 for treating Leber’s congenital amaurosis type 2, introduces a gene encoding the retinoid isomerohydrolase enzyme using an AAV2 vector (Fischer, 2017). Here, RPE65 is linked to Leber congenital amaurosis 2.